667865-69-2

TS-021 is a dipeptidyl peptidase 4 (DPP-4) inhibitor potentially for the treatment of type 2 diabetes. TS-021 and/or metformin significantly improved glucose tolerance and glucagon-like peptide-1 (GLP-1) level, and TS-021 alone or in combination with metformin significantly increased the plasma insulin level after nutrient ingestion. In the chronic treatment study, TS-021 in combination with metformin significantly lowered the glycosylated hemoglobin level, plasma insulin level, and α-cell-to-β-cell area ratio in pancreatic islets. TS-021 exhibited a significant improvement in glucose tolerance by increasing the plasma insulin level during oral glucose tolerance tests.

TS-021 是一种选择性、口服、可逆和长效的 DPP-IV 抑制剂，对 DPP-8 (> 600 倍)、DPP-9 (> 1200 倍) 和其他肽酶 (> 15,000 倍) 表现出显著的抑制选择性。TS-021 抑制人血浆中的 DPP-IV 活性，IC50 值为 5.34 nM。TS-021 具有长期持续的血浆药物浓度和强大的抗高血糖活性，并增加 GLP-1 的活性形式。